Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.

Cancer cytopathology - 1 Apr 2026

Dai Min, San Lucas Francis Anthony, Alvarez Hector, Ballester Leomar, Chen Hui, Patel Keyur P, Rashid Asif, Rao Shun, Routbort Mark J, Sura Gloria, Sweeney Keith, Toruner Gokce, Wei Peng, Yang Richard, Dang Hyvan, Luthra Rajyalakshmi, Roy-Chowdhuri Sinchita

Abstract excerpt

BACKGROUND: PD-L1 expression and tumor mutational burden (TMB) are biomarkers for immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC); however, patients harboring oncogenic alterations have limited benefit from ICIs. The impact of oncogenic alterations on TMB and PD-L1 tumor proportion score in lung cytology specimens is poorly understood. Herein, the association between oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Cytodiagnosis

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41891376
DOI: 10.1002/cncy.70090
PMCID: PMC13022943

Genes

KRAS
BRAF
EGFR
ERBB2
ALK
MET
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.PMID 41891376Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.Semantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read ↗

Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations.Semantic proximity Read ↗

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.Semantic proximity Read ↗

Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.